FIELD: biotechnology.
SUBSTANCE: disclosed are new humanised antibodies specifically binding to IL-4, and new bispecific antibodies which specifically bind to IL-4 and IL-13. Invention also involves using antibodies for treating or preventing IL-4 mediated diseases or disorders.
EFFECT: there are presented antibodies binding IL-4 and/or IL-13, and their application.
20 cl, 2 dwg, 8 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
ANTIBODIES BINDING IL-4 AND/OR IL-13, AND USE THEREOF | 2015 |
|
RU2705551C2 |
ANTIBODIES BINDING IL-4 AND/OR BL-13 AND THEIR APPLICATION | 2008 |
|
RU2488595C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
ANTI-IL-6 ANTIBODIES, METHODS AND USING | 2002 |
|
RU2318829C2 |
IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
Authors
Dates
2020-05-18—Published
2015-09-29—Filed